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Abstract
Background: Genetic polymorphisms of DNA repair enzymes in the base excision repair (BER) pathway,
may lead to genetic instability and lung cancer carcinogenesis. We investigated the interactions among the
gene polymorphisms in DNA repair genes and lung cancer.
Methods:  We analyzed associations among OGG1  Ser326Cys and MUTYH  Gln324His gene
polymorphisms in relation to lung cancer risk using PCR-RFLP. The study involved 108 lung cancer patients
and 121 non-cancer controls divided into non-smokers, smokers according to pack-years smoked in
Japanese.
Results: The results showed that the MUTYH His/His genotype compared with Gln/Gln genotype showed
an increased risk for lung cancer (adjusted odds ratio [OR] 3.03, confidence interval [95%CI], 1.31–7.00,
p = 0.010), whereas there was no significant increase for the Gln/His genotype (adjusted OR 1.35, 95%CI
0.70–2.61, p = 0.376). The MUTYH His/His genotype was at a borderline increased risk for both
adenocarcinoma and squamous cell carcinoma (adjusted OR 2.50, 95%CI 0.95–6.62, p = 0.065 for
adenocarcinoma; adjusted OR 3.20, 95%CI 0.89–11.49, p = 0.075 for squamous cell carcinoma,
respectively). However, the OGG1 Ser/Cys or Cys/Cys genotypes compared with the Ser/Ser genotype did
not have significantly increased risk for lung cancer, containing either adenocarcinoma or squamous cell
carcinoma. The joint effect of tobacco exposure and the MUTYH His/His genotype compared with the Gln/
Gln genotype showed a significant association with lung cancer risk in smokers, and there was not
significantly increased in non-smokers (adjusted OR 3.82, 95%CI 1.22–12.00, p = 0.022 for smokers;
adjusted OR 2.60, 95%CI 0.60–11.25, p = 0.200 for non-smokers, respectively). The effect of tobacco
exposure and the OGG1 Ser326Cys showed also no significant risk for lung cancer.
Conclusion: Our findings suggest that the MUTYH Gln324His polymorphism appear to play an important
role in modifying the risk for lung cancer in the Japanese population.
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Background
Lung cancer is a well-known cancer that is caused by car-
cinogens, such as those in tobacco smoke. Tobacco smoke
contains many chemical carcinogens and reactive oxygen
species, including polycyclic aromatic hydrocarbons.
DNA damage induced by these carcinogens or by endog-
enous metabolic processes can be converted into gene
mutations. Recently, in a hospital-based patient-control
study, we reported that genetic polymorphisms of NAT2
and CYP1A2 in metabolic processes contributed to lung
cancer susceptibility depending on smoking status in Jap-
anese population [1].
Genetic variation in DNA repair genes are thought to
modulate DNA repair capacity and are suggested to be
related to cancer risk [2]. The base excision repair (BER)
pathway, one of the DNA repair pathways, plays an
important role in repairing the DNA damage resulting
from chemical alterations of a single base, such as meth-
ylated, oxidized, or reduced bases [3]. The most stable
product of oxidative DNA damage, 8-oxo-7, 8-dihydro-2'-
deoxyguanosine (8-oxoG), causes G:C→T:A transver-
sions, because 8-oxoG pairs with adenine as well as cyto-
sine [4]. In human cells, the proteins that repair these
mutations are 8-oxo-guanine glycosylase-1 (OGG1),
which is involved in direct repair by 8-oxoG DNA glycosy-
lase, and mutY homolog (MUTYH), which is involved in
repair of adenine to 8-oxoG mismatch or that of guanine
to 1,2-dihydro-2-oxoadenine (2-OH-A) mismatch due to
its glycosylase activity [5,6].
In this study, we focused on OGG1  Ser326Cys
(rs1052133) and MUTYH  Gln324His (rs3219489). In
some patient-control studies, OGG1 Ser326Cys appeared
to be associated with an increased risk for lung cancer [7-
9], whereas the findings of this association study have
been inconsistent [10]. In MUTYH gene, it was shown that
the inherited variants Tyr165Cys and Gly382Asp have
been associated with colorectal tumors in Caucasians, not
in East Asians including Japanese [11-13]. The other pol-
ymorphism,  MUTYH  Gln324His, have been associated
with colorectal tumors in a Japanese population [14,15].
Our recent study found that the MUTYH Gln324His con-
stitutes an increased risk of colorectal cancer [16]. To our
knowledge, no previous report has examined the effect of
MUTYH Gln324His with a functional partner of OGG1,
for lung cancer and the significant role of base excision
repair genes for oxidative damage in relation to smoking.
We also investigated two gene variants in lung cancer with
the histological subtypes of adenocarcinoma and squa-
mous cell carcinoma; smoking act differently in the devel-
opment of various histologic types of lung cancer [17].
Therefore, we specifically examined whether two gene
polymorphisms,  OGG1  Ser326Cys and MUTYH
Gln324His play an interactive role in the risk for lung can-
cer incidence in relation to the histological subtypes and
the smoking status.
Materials and methods
Study subjects
The lung cancer patients and controls in this small
patient-control study were included in a previous study
that investigated the genetic polymorphisms of metabolic
enzymes [1]. The 108 lung cancer patients (67 with lung
adenocarcinoma, 31 with lung squamous cell carcinoma,
and 10 with other carcinomas) were recruited between
April 2001 and July 2002 at the Hyogo Medical Center for
Adults in Akashi City, Japan. The 121 controls who were
selected from outpatients with no current or previous
diagnosis of cancer were recruited between November
2002 and March 2003. They suffered mainly from: gas-
trointestinal disease, hypertension and diabetes.
Informed consent was obtained and detailed exposure
data on smoking was collected by a personal interview.
The study design was approved by the Ethics Review Com-
mittee on Genetic and Genomic Research, Kobe Univer-
sity Graduate School of Medicine. Informed consent was
obtained from all patients and controls, and all samples
were coded after collection of blood and data (question-
naire on smoking habits, etc.). The amount of smoke
exposure was calculated as pack-years, the product of the
number of years an individual smoked and the average
number of cigarettes smoked per day (converted into a
standard pack of 20 cigarettes).
Genotyping
The genomic DNA to be used was isolated for the previous
study [1]. The genotype of OGG1  Ser326Cys [7] and
MUTYH Gln324His [16] was determined by PCR-RFLP
analysis, as described previously.
Statistical analysis
Statistical analysis was performed with the SPSS software
package (version 14.0 for Windows; SPSS Japan Inc.,
Tokyo, Japan). Hardy-Weinberg equilibrium was tested
using the goodness-of-fit Chi-square test to compare the
observed genotype frequencies with the expected geno-
type frequencies among the control subjects. Associations
were expressed as odds-ratios (OR) with 95% confidence
interval (95% CI) and p < 0.05 was considered statistically
significant. Logistic regression analysis was performed to
assess the association between each genotype and lung
cancer. ORs, which were computed to estimate the associ-
ation between certain genotypes and lung cancer, were
adjusted for age, gender, and smoking habit (number of
pack-years smoked). The subjects were divided into two
groups according to pack-years smoked: never-smokers
(pack-years = 0) and ever-smokers (pack-years > 0).Journal of Experimental & Clinical Cancer Research 2009, 28:10 http://www.jeccr.com/content/28/1/10
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Results
We present the characteristics of lung cancer in Table 1,
including 108 patients and 121 controls. There was no
difference in the gender distribution (p = 0.491) between
males (patients, 65.7%; controls, 61.2%) and females
(patients, 34.3%; controls, 38.8%). There was no differ-
ence in the average ages (± SD) between patients (65.5 ±
9.4 years) and controls (67.4 ± 6.7 years) (p = 0.078).
Non-smokers comprised 29.6% of patients and 45.5% of
controls and smokers comprised 68.5% of patients and
49.6% of controls. There was also no difference in the
average pack-years (± SD) between patients (33.8 ± 31.7)
and controls (25.6 ± 35.1) (p = 0.069). Histological types
of the patients were: 67 adenocarcinoma (62.0%), 31
squamous cell carcinoma (28.7%) and 10 others (9.3%).
Genotyping results of OGG1  Ser326Cys and MUTYH
Gln324His adjusted for gender, age, and smoking habit
along with allele frequencies are shown in Table 2. The
allele frequencies of the two gene polymorphisms in con-
trols were consistent with the Hardy-Weinberg equilib-
rium. The crude and adjusted ORs for the OGG1 Ser/Cys or
Cys/Cys  genotypes compared with the Ser/Ser  genotype
were not statistically significant. The crude and adjusted
ORs for the MUTYH His/His genotype compared with Gln/
Gln  genotype showed a increased risk for lung cancer
(crude odds ratio [OR] 3.25, 95% confidence interval
[95%CI] 1.44–7.36, p = 0.005; adjusted OR 3.03, 95%CI
1.31–7.00, p = 0.010, respectively), whereas there was no
significant increase for the Gln/His genotype (crude OR
1.39, 95%CI 0.74–2.62, p = 0.309; adjusted OR 1.35,
95%CI 0.70–2.61, p = 0.376, respectively).
Table 3 summarizes the genotype distribution for lung
adenocarcinoma and squamous cell carcinoma, showing
the OR adjusted for gender, age, and smoking habits. The
crude and adjusted ORs for the OGG1 Ser/Cys or Cys/Cys
genotypes compared with the Ser/Ser genotype were not
significant for adenocarcinoma and squamous cell carci-
noma. The crude ORs for the MUTYH His/His genotype
compared with Gln/Gln  genotype showed a significant
increase for both adenocarcinoma and squamous cell car-
cinoma (OR 3.04, 95%CI 1.18–7.82, p = 0.021 for aden-
ocarcinoma; OR 4.11, 95%CI 1.27–13.33, p = 0.019,
respectively). The adjusted ORs for the MUTYH His/His
genotype compared with Gln/Gln genotype showed a bor-
derline significant for adenocarcinoma and squamous cell
carcinoma (OR 2.50, 95%CI 0.95–6.62, p = 0.065 for ade-
nocarcinoma; OR 3.20, 95%CI 0.89–11.49, p = 0.075 for
squamous cell carcinoma, respectively). While, there was
no significant increase for the MUTYH Gln/His genotype
in the histological types.
The ORs for the combined effect of tobacco exposure
(pack-years smoked) and the two polymorphisms,
adjusted for gender and age, are shown in Table 4. The
crude and adjusted ORs for the OGG1 Ser/Cys or Cys/Cys
genotypes compared with the Ser/Ser genotype showed no
Table 1: Characteristics of lung cancer case and control subjects
Patients Controls
Item n % n % P-value
Number 108 121
Gender
m a l e s 7 16 5 . 77 46 1 . 2 0 . 4 9 1 a
f e m a l e s 3 73 4 . 34 73 8 . 8
Age
~ 6 4 4 03 7 . 05 04 1 . 3
6 5 ~ 6 9 1 71 5 . 72 92 4 . 0
7 0 ~ 7 4 3 02 7 . 82 01 6 . 5
7 5 ~ 1 91 7 . 62 21 8 . 2
unknown 2 1.9 0 0.0
Mean ± S.D. 65.5 ± 9.4 67.4 ± 6.7 0.078b
Smoking status (Pack-years)
Never (Pack-years = 0) 32 29.6 55 45.5
Ever (Pack-years > 0) 74 68.5 60 49.6
unknown 2 1.9 6 5.0
Mean ± S.D. 33.8 ± 31.7 25.6 ± 35.1 0.069b
Histological type
adenocarcinoma 67 62.0
squamous cell carcinoma 31 28.7
others 10 9.3
a: χ2 analysis
b: Student's T-testJournal of Experimental & Clinical Cancer Research 2009, 28:10 http://www.jeccr.com/content/28/1/10
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statistically significant risk in non-smokers and smokers.
The crude and adjusted ORs for the MUTYH His/His gen-
otype compared with the Gln/Gln genotype showed a sig-
nificant association with lung cancer risk in smokers
(crude OR 3.50, 95%CI 1.13–10.83, p = 0.030; adjusted
OR 3.82, 95%CI 1.22–12.00, p = 0.022, respectively), and
there was not statistically significant in non-smokers
(crude OR 3.20, 95%CI 0.81–12.65, p = 0.097; adjusted
OR 2.60, 95%CI 0.60–11.25, p = 0.200, respectively). The
crude and adjusted ORs for the MUTYH Gln/His genotype
compared with the Gln/Gln genotype showed no statisti-
cally significant risk in non-smokers and smokers.
Discussion
Herein, we report that gene polymorphisms, OGG1
Ser326Cys and MUTYH Gln324His, of two DNA repair
genes in the BER pathway can modulate lung cancer risk
in a small case-control study. Our results indicated that
lung cancer risk was found to be 3-fold in individuals with
the homozygous His/His genotype of MUTYH Gln324His
(95%CI 1.31–7.00, p = 0.010), whereas that was not with
that of OGG1 Ser326Cys. The MUTYH His/His genotype
also show a borderline significant risk for both adenocar-
cinoma and squamous cell carcinoma. Moreover, a joint
effect between tobacco smoking and the MUTYH His/His
genotype for the risk of lung cancer was statistically
Table 2: Genotype distribution in lung cancer and Allele frequency
Allele frequency
Genotype patients
(n = 108)
controls
(n = 121)
crude adjusted patients controls
n % n % OR (95%CI) P-value OR (95%CI)a P-value % %
OGG1
Ser/Ser 27 25.0 39 32.2 1.00 1.00 Ser 0.505 0.546
Ser/Cys 55 50.9 54 44.6 1.47 (0.79–2.73) 0.221 1.52 (0.80–2.91) 0.204 Cys 0.495 0.455
Cys/Cys 26 24.1 28 23.1 1.34 (0.65–2.77) 0.427 1.47 (0.69–3.12) 0.313
MUTYH
Gln/Gln 22 20.3 37 30.6 1.00 1.00 Gln 0.468 0.591
Gln/His 57 52.8 69 57.0 1.39 (0.74–2.62) 0.309 1.35 (0.70–2.61) 0.376 His 0.532 0.409
His/His 29 26.9 15 12.4 3.25 (1.44–7.36) 0.005 3.03 (1.31–7.00) 0.010
a: OR adjusted for gender, age, smoking habit
Table 3: Genotype distribution in relation to histological type in lung cancer
Genotype Adenocarcinoma Squamous Cell Carcinoma
patients
(n = 67)
controls
(n = 121)
crude adjusted patients
(n = 31)
controls
(n = 121)
crude adjusted
n%n% O R
(95%CI)a
P-value OR
(95%CI)a
P-value n % n % OR
(95%CI)a
P-value OR
(95%CI)a
P-value
OGG1
Ser/Ser 17 25.4 39 32.2 1.00 1.00 8 25.8 39 32.3 1.00 1.00
Ser/Cys 33 49.2 54 44.6 1.40
(0.69–2.87)
0.355 1.34
(0.64–2.81)
0.439 16 51.6 54 44.6 1.44
(0.56–3.71)
0.445 1.23
(0.44–3.43)
0.695
Cys/Cys 17 25.4 28 23.1 1.39
(0.61–3.19)
0.434 1.31
(0.56–3.08)
0.530 7 22.6 28 23.1 1.22
(0.40–3.75)
0.730 1.54
(0.45–5.23)
0.491
MUTYH
Gln/Gln 13 19.4 37 30.6 1.00 1.00 6 19.4 37 30.6 1.00 1.00
Gln/His 38 56.7 69 57.0 1.57
(0.74–3.30)
0.237 1.55
(0.72–3.32)
0.263 15 48.4 69 57.0 1.34
(0.48–3.75)
0.576 1.00
(0.33–3.01)
0.999
His/His 16 23.9 15 12.4 3.04
(1.18–7.82)
0.021 2.50
(0.95–6.62)
0.065 10 32.3 15 12.4 4.11
(1.27–13.33)
0.019 3.20
(0.89–11.49)
0.075
a: OR adjusted for gender, age, smoking habitJournal of Experimental & Clinical Cancer Research 2009, 28:10 http://www.jeccr.com/content/28/1/10
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increased in smokers, whereas that was not in non-smok-
ers.
We found that no significant effect was apparent between
OGG1 Ser326Cys and lung cancer risk, in combination to
smoking status. It has been reported that the OGG1 Cys
allele in Japanese patients is associated with an increased
risk for lung cancer [8,9]. The variant OGG1 is deficient in
its catalytic activity, was not stimulated by the AP endonu-
clease [18]. A recent report has suggested that OGG1
Ser326Cys is not associated with lung cancer by meta-
analysis [10]. Therefore, our finding in a Japanese popula-
tion is consistent with the results from the meta-analysis
study.
On the other hand, we found that the MUTYH His/His
genotype was significantly associated with increased risk
of lung cancer. Previous study has shown that the identi-
fied variants of the MUTYH gene, containing Gln324His,
were unlikely to predispose significantly to the risk for
lung cancer in Caucasians [19]. The discrepancy between
this study and ours might reflect the differences in genetic
background, carcinogen exposure in different populations
or sample sizes. Recent study has reported that the
MUTYH enzyme activity in Gln324His polymorphism
was only 66% active from the substrates compared with
the wild type [20]. It was reported that the 2-OH-A level
compared to repair of adenine opposite 8-oxo-G was
increased in human cancerous tissues compared to nor-
mal tissues [21]. Therefore, it is also possible that the
MUTYH enzyme having 324His variation may have par-
tially a reduced activity in repair of 2-OH-A opposite gua-
nine. This suggested that MUTYH Gln324His might also
be associated with risk for lung cancer, related to the
decreased MUTYH enzyme activity.
In different histological types of lung cancer, MUTYH His/
His genotype was a significantly borderline association for
both adenocarcinoma and squamous cell carcinoma, that
suggested a potential interaction between this polymor-
phism and lung cancer risk regardless these subtypes.
Moreover, the result of the joint effect between tobacco
smoking and MUTYH His/His genotype for the risk of lung
cancer was a significant increase in smokers, whereas that
was not in non-smokers. If the sample size had been
larger, the result in non-smokers might have been signifi-
cant. This finding suggested that the effect of MUTYH
Gln324His for lung cancer risk is not different between
smoking habits.
In conclusion, these results suggest that the MUTYH
Gln324His polymorphism appear to play an important
role in modifying the risk for lung cancer in the Japanese
population. To the best of our knowledge, our study is the
first case-control study to evaluate the association
between the MUTYH Gln324His and lung cancer risk in
Japanese. The MUTYHGln324His polymorphism may be
one of useful markers of genetic susceptibility to lung can-
cer and require further verification as predictive biomark-
ers in a larger study population.
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Table 4: Genotype distribution in relation to smoking status in lung cancer
Non-smokers Smokers
Genotype (Pack-years = 0) (Pack-years > 0)
patients
(n = 32)
controls
(n = 55)
crude adjusted patients
(n = 74)
controls
(n = 60)
crude adjusted
n%n% O R
(95%CI)a
P-value OR
(95%CI)a
P-value n % n % OR
(95%CI)a
P-value OR
(95%CI)a
P-value
OGG1
Ser/Ser 5 15.6 14 25.5 1.00 1.00 20 27.0 23 38.3 1.00 1.00
Ser/Cys 20 62.5 26 47.3 2.15
(0.67–6.98)
0.201 2.49
(0.72–8.57)
0.148 35 47.3 25 41.7 1.61
(0.73–3.54)
0.237 1.53
(0.69–3.40)
0.292
Cys/Cys 7 21.9 15 46.9 1.31
(0.34–5.09)
0.700 1.38
(0.34–5.64)
0.654 19 25.7 12 20.0 1.82
(0.71–4.66)
0.211 1.81
(0.70–4.65)
0.219
MUTYH
Gln/Gln 5 15.6 18 32.7 1.00 1.00 17 23.0 17 28.3 1.00 1.00
Gln/His 19 59.4 28 50.9 2.44
(0.77–7.71)
0.128 2.06
(0.63–6.76)
0.233 36 48.6 37 61.7 0.97
(0.43–2.20)
0.947 1.07
(0.47–2.46)
0.867
His/His 8 25.0 9 16.4 3.20
(0.81–12.65)
0.097 2.60
(0.60–11.25)
0.200 21 28.4 6 10.0 3.50
(1.13–10.83)
0.030 3.82
(1.22–12.00)
0.022
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